Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EPO Use OK In All But Eight Cancer Conditions, Medicare NCD Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Final National Coverage Determination issued July 30 drops number of restricted uses of erythropoiesis-stimulating agents from the 13 listed in the draft NCD.

You may also be interested in...



Nplate, ESAs In ESRD Setting On List For Potential National Coverage Action By CMS

Agency seeks public comment on proposed list of drugs, devices and treatments that could get reimbursement scrutiny through the national coverage determination process.

Nplate, ESAs In ESRD Setting On List For Potential National Coverage Action By CMS

Agency seeks public comment on proposed list of drugs, devices and treatments that could get reimbursement scrutiny through the national coverage determination process.

2009 Medicare Budget Plan Pushes For ESA Bundling With Dialysis Rates

Single-payment proposal comes with no details on how the system would function.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel